Cancer du poumon et irradiation ganglionnaire prophylactique : un débat clos ?

Laurans, M.; Botticella, Angela; Moukasse, Y.; Lévy, Antonin; Péchoux, C. Le

doi:10.1016/j.canrad.2019.06.008

Cited by 5 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the immune checkpoint inhibitor + intensity-modulated radiation therapy era, IFRT is commonly used for advanced lung cancer (3,12). However, some patients were treated with IFRT experience lymph node recurrence (4).…”

Section: Discussionmentioning

confidence: 99%

Impact of digital positron emission tomography/computed tomography on the delineation of clinical target volume in advanced lung cancer

Makita,

Hamamoto,

Kanzaki

et al. 2023

Mol Clin Oncol

View full text Add to dashboard Cite

The present study investigated the differences between digital [18F]-Fluorodeoxyglucose (FDG) positron emission tomography [PET]/computed tomography [CT] (dPET/CT) and conventional PET/CT (cPET/CT) in delineating the clinical target volume (CTV) in patients with advanced lung cancer in the involved field radiation therapy (IFRT) era. Patients with advanced lung cancer were scanned using two dual-imaging protocols (dPET/CT and cPET/CT). Two virtual delineations contoured with reference to dPET/CT and cPET/CT images were created for each patient by five radiation oncologists. Changes in the delineation of target volumes in each patient were examined. A total of 10 patients [male/female, 9/1; median age, 65 years (range, 58-80 years)] were enrolled between April 2020 and September 2020. Significant changes in the delineation of CTVs were uncommon between dPET/CT and cPET/CT. A notable increase in CTVn was observed in 10% of the patients (1/10; P<0.05; Smirnov-Grubbs analysis). In this patient, a node that was not assessed as lymph node metastasis when cPET/CT was used was assessed as lymph node metastasis when dPET/CT was used and was included in the CTVn by all five radiation oncologists. In patients with advanced lung cancer, notable changes in CTV delineations are uncommon, regardless of whether dPET/CT or cPET/CT is used. However, in some cases, CTVn delineation with reference to dPET/CT may improve the treatment outcomes of IFRT for advanced lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of digital positron emission tomography/computed tomography on the delineation of clinical target volume in advanced lung cancer

Makita,

Hamamoto,

Kanzaki

et al. 2023

Mol Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Pathologically confirmed lymph nodes on endoscopic ultrasound with or without fine needle aspiration techniques/mediastinoscopy, if available, should also be included. Smaller fields have led to decreased toxicity without compromising locoregional control rates (34,35). The radiotherapy volume was investigated in an important study by the Southwest Oncology Group (SWOG), which randomized patients after induction chemotherapy to receive irradiation of the post-chemotherapy residue or irradiation of the prechemotherapy volume.…”

Section: Volumes Of Irradiationmentioning

confidence: 99%

Thoracic radiotherapy in small cell lung cancer—a narrative review

Lévy¹,

Botticella²,

Péchoux³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Small-cell lung cancer (SCLC) represents 10-15% of all lung cancers and has a poor prognosis.Thoracic radiotherapy plays a central role in current SCLC management. Concurrent chemoradiotherapy (CTRT) is the standard of care for localised disease (stage I−III, limited-stage, LS). Definitive thoracic radiotherapy may be offered in metastatic patients (stage IV, extensive stage, ES-SCLC) after chemotherapy.For LS-SCLC, the gold standard is early accelerated hyperfractionated twice-daily CTRT (4 cycles of cisplatin etoposide, starting with the first or second chemotherapy cycle). Modern radiation techniques should be used with involved-field radiotherapy based on baseline CT and PET/CT scans. In ES-SCLC, thoracic radiotherapy should be discussed in cases of initial bulky mediastinal disease/residual thoracic disease not progressing after induction chemotherapy. This strategy was however not assessed in recent trials establishing chemo-immunotherapy as the standard first line treatment in ES-SCLC. Future developments include technical radiotherapy advances and the incorporation of new drugs. Thoracic irradiation is delivered more precisely given technical developments (IMRT, image-guided radiotherapy, stereotactic radiotherapy), reducing the risks of severe adverse events. Stereotactic ablative radiotherapy may be discussed in rare early stage (T1 to 2, N0) inoperable patients. A number of current clinical trials are investigating immunoradiotherapy. In this review, we highlight the current role of thoracic radiotherapy and describe ongoing research in the integration of biological surrogate markers, advanced radiotherapy technologies and novel drugs in SCLC patients.

show abstract

Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration

Chen

Tang

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Background. Increasing evidence supports that immune cell infiltration (ICI) patterns play a key role in the tumor progression of lung squamous cell carcinoma (LUSC). However, to date, the immune infiltration picture of LUSC has not been elucidated. Method. TCGA was used to download multiomics data from LUSC samples. At the same time, we included two datasets on lung squamous cell carcinoma, GSE17710 and GSE157010. To reveal the landscape of tumor immune microenvironment (TIME), the ESTIMATE algorithm, ssGSEA approach, and CIBERSORT analysis are used. To quantify the ICI pattern in a single tumor, consistent clustering is used to determine the LUSC subtype based on the ICI pattern, and principal component analysis (PCA) is used to obtain the ICI score. The prognostic value of the Kaplan-Meier curves is confirmed. GSEA (Gene Set Enrichment Analysis) was used to perform functional annotation. To investigate the immunotherapeutic effects of the ICI score, the immunophenotyping score (IPS) is used. Finally, analyze the mutation data with the “maftools” R package. Results. We identified four different immune infiltration patterns with different prognosis and biological characteristics in 792 LUSC samples. The identification of ICI patterns in individual tumors developed under ICI-related characteristic genes based on the ICI score helps to analyze the biological process, clinical results, immune cell infiltration, immunotherapy effects, and genetic variation. Immune failure is indicated by a high ICI score subtype marked by immunosuppression. Patients with low ICI scores have an abundance of efficient immune cells, which corresponds to the immunological activation phenotype and may have therapeutic benefits. The immunophenotypic score was used as a surrogate indicator of immunotherapy results, and samples with low ICI scores obtained significantly higher immunophenotypic scores. Finally, the relationship between the ICI score and tumor mutation burden (TMB) was proven. Conclusion. This study fully clarified the indispensable role of the ICI model in the complexity and diversity of TIME. The quantitative identification of ICI patterns in a single tumor will help draw the picture of TIME and further optimize precision immunotherapy.

show abstract

Cancer du poumon et irradiation ganglionnaire prophylactique : un débat clos ?

Cited by 5 publications

References 79 publications

Impact of digital positron emission tomography/computed tomography on the delineation of clinical target volume in advanced lung cancer

Impact of digital positron emission tomography/computed tomography on the delineation of clinical target volume in advanced lung cancer

Thoracic radiotherapy in small cell lung cancer—a narrative review

Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration

Contact Info

Product

Resources

About